Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ImmunityBio, Inc. before investing.

In this article, we go over a few key elements for understanding ImmunityBio, Inc.’s stock price such as:

• ImmunityBio, Inc.’s current stock price and volume
• Why ImmunityBio, Inc.’s stock price changed recently
• Upgrades and downgrades for IBRX from analysts
• IBRX’s stock price momentum as measured by its relative strength

About ImmunityBio, Inc. (IBRX)

Before we jump into ImmunityBio, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

Want to learn more about ImmunityBio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ImmunityBio, Inc..

ImmunityBio, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, ImmunityBio, Inc.’s stock price was $2.360.

ImmunityBio, Inc. is up 10.8% from its previous closing price of $2.130.

During the last market session, ImmunityBio, Inc.’s stock traded between $2.250 and $2.450. Currently, there are approximately 946.60 million shares outstanding for ImmunityBio, Inc..

ImmunityBio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ImmunityBio, Inc. Stock Price History

ImmunityBio, Inc.’s (IBRX) price is currently down 1.67% so far this month.

During the month of November, ImmunityBio, Inc.’s stock price has reached a high of $2.450 and a low of $1.950.

Over the last year, ImmunityBio, Inc. has hit prices as high as $5.160 and as low as $1.830. Year to date, ImmunityBio, Inc.’s stock is down 7.81%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ImmunityBio, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of November 28, 2025,, no analysts have changed their rating of ImmunityBio, Inc.’s stock over the last month.

Additionally, you'll want to evaluate ImmunityBio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ImmunityBio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ImmunityBio, Inc. (IBRX) by visiting AAII Stock Evaluator.

Relative Price Strength of ImmunityBio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, ImmunityBio, Inc. has a weighted four-quarter relative price strength of -16.40%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how ImmunityBio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ImmunityBio, Inc. Stock Price: Bottom Line

As of November 28, 2025, ImmunityBio, Inc.’s stock price is $2.360, which is up 10.8% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ImmunityBio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.